l e t t e r s 
l e t t e r s homozygous for the deletion (Fig. 1b, Supplementary Fig. 1 and Supplementary Table 1) . Notably, all 16 Vel-negative clinical cases ( Supplementary Fig. 3 ) who carried antibodies against Vel, confirming their Vel-negative status with extremely high confidence, were homozygous for the deletion. Given the population frequency of the deletion, this replication is highly significant (P = 1 × 10 −58 ). Further, 19 out of 20 individuals with weak Vel expression were heterozygous for the deletion (Fig. 1b) ; the remaining individual was heterozygous for a new missense mutation encoding a p.Met51Lys alteration. This finding shows that heterozygous deletion of SMIM1 underlies weak expression of the Vel antigen. Finally, six individuals classified as Vel negative were heterozygous for the deletion or a second, different missense mutation replacing Met51 with an arginine. Heterozygosity for the null allele in these individuals is most likely explained by misclassification of extremely weak Vel expression as Vel negative (Online Methods). For one case (unique study number (USN) 48), we were able to retrieve RBCs, and this case was indeed weakly positive for the Vel antigen (Supplementary Fig. 1 ). From the extremely weak Vel expression in the individuals with missense mutations, we infer that these mutations may lead to inability of the SMIM1 protein to incorporate in the membrane 4, 5 , or, alternatively, it is possible that these mutations only modify the epitope, leading to greatly reduced binding of the polyclonal antibody to Vel. Further experiments are needed to determine the functional consequences of these missense mutations.
We next validated this finding in vitro by overexpressing human SMIM1 cDNA in HEK293T cells ( Fig. 1c and Online Methods). The Vel antigen was identified by flow cytometry using human immunepurified antibody to Vel. Nearly all of the SMIM1-transfected cells expressed the Vel antigen. Taken together with our genetic findings, this identifies SMIM1 as the gene underlying the Vel blood group.
The individuals classified as having weak Vel expression generally had extremely low amounts of the Vel antigen. We therefore hypothesized that these individuals carry a modifier allele that lowers the transcription of SMIM1 on the copy not disrupted by the deletion. The major allele (the A reference allele, allele frequency of 77% in the UK10K cohort) of the common variant rs1175550, located in the second intron of SMIM1, was strongly associated (P = 1 × 10 −250 ) with decreased SMIM1 transcript levels in an eQTL study in whole blood in 1,240 individuals 6 (Fig. 2a) and explains more than 60% of the variation in SMIM1 transcript levels in the population. This SNP is located in a regulatory region in erythroblasts, the precursor cells of RBCs, with clear transcription factor binding at this position in a myeloid-erythroid cell line (Fig. 2b) but not in a lymphoid cell line, which is compatible with its pattern of expression as determined by the sequencing of RNA from primary human blood cell progenitors and precursors ( Fig. 2c and Supplementary Fig. 4 ). Greater binding of nuclear proteins to the major (A) allele compared to the minor (G) allele of this variant (Supplementary Fig. 5 ) suggests that repressive factors reduce the level of SMIM1 transcription. All 24 Vel-negative individuals or those with weak Vel expression who were heterozygous for the deletion were homozygous for the major allele of rs1175550; the Vel-negative individual heterozygous for rs1175550 and the missense mutation carried the A allele of rs1175550 on the wild-type haplotype without the missense mutation (Fig. 1b) . On the basis of its frequency in the UK10K cohort, the probability of observing the major allele of rs1175550 on the non-deletion chromosome in 24 individuals by chance is P = 0.003. This, therefore, suggests that the SMIM1 eQTL, rs1175550, contributes to variable expression of the Vel antigen SMIM1; we hypothesize that individuals heterozygous for the deletion but carrying the minor allele of rs1175550 on the nondeletion haplotype are normal, Vel-positive individuals.
SMIM1 was only recently annotated as a protein-coding gene and has no known function. The SMIM1 protein contains a single stretch of 22 hydrophobic residues (from Val53 to Val74), which is of sufficient length to act as a transmembrane domain. To assign a possible biological role to SMIM1, we considered a recent meta-analysis of genome-wide association studies (GWAS) in nearly 72,000 individuals of 6 RBC parameters 3 . Indeed, the major allele of the common variant rs1175550 is associated with decreased mean hemoglobin concentration in RBCs (P = 8.6 × 10 −15 ) and is associated at nominal significance levels with RBC count (P = 0.005), hemoglobin concentration (P = 0.001) and mean RBC volume (P = 4.5 × 10 −6 ), which are all correlated parameters 3 . The major allele was also strongly associated (P = 1 × 10 −250 ) with lower SMIM1 transcript levels, as noted above (Fig. 2a) . We found that the association signal for SMIM1 in the eQTL study and the association signal for RBC hemoglobin concentration colocalized (Fig. 2d) . A second SNP, rs1184341, which is in strong linkage disequilibirum (LD) with rs1175550 (r 2 = 0.92) but which was not directly tested in the gene expression study and the GWAS, also showed strong evidence for colocalization (Supplementary Fig. 6 ). 
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Additionally, we did not identify other target genes for the rs1175550 eQTL (at false discovery rate (FDR) < 0.05). These results strongly suggest that SMIM1 mediates the effect of the GWAS signal. On the basis of this finding, we conclude that SMIM1 affects the mean hemoglobin concentration of RBCs, although the effect size is likely to be small according to the GWAS result, and the precise causative variant(s) remain to be identified. The role for SMIM1 in the formation and hemoglobinization of RBCs was further supported by a largescale gene coexpression analysis (Supplementary Table 2 ).
To establish the biological relevance of SMIM1 in RBC formation in vivo, we performed morpholino-mediated knockdown in zebrafish. Over the years, zebrafish has proven its suitability as a model system for furthering the understanding of hematopoiesis in humans 7, 8 . SMIM1 has evolved under strong purifying selection ( Supplementary Fig. 7 ). The second protein-coding exon of human SMIM1, which encodes the transmembrane domain, is well conserved with the zebrafish ortholog smim1 we identified ( Supplementary  Fig. 7 ). Knockdown of smim1 resulted in mild but consistent reduction in the number of RBCs compared with control embryos ( Fig. 3 and Supplementary Fig. 8 ). This observation is consistent with the effect of reduced SMIM1 transcript levels on the average hemoglobin content of human RBCs, as hemoglobin availability is a critical determinant of the number of RBCs.
We investigated RBC and iron homeostasis parameters in 12 Velnegative blood donors and observed a weak but nonsignificant trend suggestive of depletion in iron reserves (data not shown). Low iron concentration is the most common cause of low hemoglobin levels, and it should be taken into account that females and males with hemoglobin levels below 12.5 and 13.5 g/dl, respectively, are removed from the donor pool. This selection may have reduced the power to observe the true effect of the SMIM1 deletion on iron reserves and hemoglobin concentration; an independent follow-up study in a large, unselected population is required to obtain an unbiased estimate of the effect of the homozygous frameshift deletion on the formation of RBCs. However, the apparently limited phenotypic consequences of homozygous deletion, the small effect size of the common SNP rs1175550 on mean RBC hemoglobin concentration and the mild phenotype in zebrafish suggest that the role for the SMIM1 protein in the regulation of RBC parameters is limited. Further studies are necessary to establish whether the frameshift deletion indeed results in complete loss of function (the frameshift occurs upstream of the region encoding the transmembrane domain) and to more fully characterize the biological and biochemical function of SMIM1.
In summary, we have identified SMIM1 as the gene underlying the Vel blood group. Our finding that homozygosity for a low-frequency 17-nucleotide deletion polymorphism underlies Vel-negative status is of direct clinical relevance, as it allows the unequivocal identification of Vel-negative blood donors, thereby preventing erroneous Vel typing and reducing the risk of severe and sometimes life-threatening destruction of incompatible donor RBCs by antibodies to Vel. Integrative analysis of a gene expression study and a meta-analysis of genetic association studies indicates that the SMIM1 eQTL rs1175550 . Each SNP has both a SMIM1 eQTL association P value (left y axis) and an MCHC association P value from the meta-analysis of GWAS for RBC parameters (right y axis). 
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Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINe MeThOdS
Phenotyping of RBCs for the Vel blood group. RBCs from nearly 350,000 nonremunerated donors in
The Netherlands and England were tested for the Vel blood group by a hemagglutination screening test (test 1) using a single polyclonal human antiserum containing antibodies to Vel (Supplementary Fig. 1 ). Test 1 is prone to high levels of false positive and false negative results. Negative samples were therefore tested by a more sensitive hemagglutination confirmatory test (test 2) with at least three different potent antibodies to Vel; however, this test does not always detect extremely low amounts of the Vel antigen (Supplementary Fig. 1) . It is therefore reasonable to assume that a fraction of samples with negative test 2 results actually have weak Vel expression. Adsorption and elution of antibody to Vel followed by titration of the eluted antibody in the hemagglutination test on Vel-positive cells (test 3) has a forensic level of sensitivity. A number of samples with discordance between SMIM1 genotype and Vel phenotype ( Supplementary  Fig. 1 ), for which cryopreserved RBCs were available, were investigated by test 3. In addition, the RBCs from tens of thousands of blood donors in Denmark (no precise records on the numbers tested were maintained) were screened by test 1 using different lots of antibody to Vel than the antisera used in The Netherlands and UK. The six samples negative in test 1 (USN45-USN50; Supplementary Table 1) were confirmed by test 2 but generally with not more than two sera against Vel. To have access to samples from individuals who were definitively Vel negative, we enrolled 16 individuals (Supplementary Fig. 3 and Supplementary Table 1) who formed antibody to Vel. In addition, another five clinical cases with antibody to Vel were enrolled, but no DNA was available. RBCs from seven siblings from seven different Vel-negative cases with antibody to Vel were investigated by test 2. Two cases were found to have weak Vel expression, and the remaining five were found to be Vel negative ( Supplementary Fig. 3 and Supplementary Table 1 ). All antibodies against Vel were obtained from Vel-negative individuals immunized against Vel by transfusion or during pregnancy. NHS Blood and Transplant used for initial identification of donors two different antisera, NHSBT-Tooting_anti-Vel_001 and NHSBT-Tooting_anti-Vel_002. Confirmation testing was typically performed with two further antisera, NHSBT-IBGRL_anti-Vel_001 and NHSBTIBGRL_anti-Vel_002, and, in a number of cases, a third, NHSBT-IBGRL_anti-Vel_003, was used. Dutch samples were typed for Vel with Sanquin_NL25, and confirmation typing was performed with some or all of the following antisera: NL04-1, NL04-2, NL05, NL07, NL14, NL15 and NL22. The immunopurified antibody to Vel NL25 was used for flow cytometry measurement of Vel expression on RBCs (Fig. 1a) .
The results obtained with the hemagglutination tests with antibody to Vel are compatible with the notion that the abundance of the Vel antigen on RBCs is low and varies substantially in the normal population. This assumption was supported by the measurement by flow cytometry of Vel abundance on the RBC membrane with the most potent immune-purified immunoglobulin G (IgG) to Vel detected by Alexa Fluor 488-labeled goat secondary antibody to human IgG (Molecular Probes, A-11013) (Fig. 1a) .
Genetic analysis. DNA was extracted from blood or saliva samples using standard laboratory procedures. The DNA samples from 5 individuals (USN1-USN5) were analyzed by exome sequencing, and all 96 samples (Supplementary Table 1) were used for genetic analysis by Sanger sequencing. The SNP rs1175550 was typed either by Sanger sequencing or with a variant-specific TaqMan probe using standard conditions. Sanger sequencing was carried out on the coding fraction and intronic flanking regions of the SMIM1 gene using the primers listed in Supplementary Table 3 . In England, consent was obtained under the Cambridge BioResource stage 1 enrolment protocol, which has been approved by the Cambridgeshire 1 Research Ethics Committee. Samples from the Dutch donors and patients were obtained with informed consent, and use of the samples of Vel-negative and Vel-weak donors was approved by the Sanquin Clinical Consultative Service. Samples in Denmark were obtained according to national regulations for consenting individuals for biomedical research.
Exome sequencing and data analysis. Libraries were prepared and indexed using the Illumina TruSeq library prep kit. Sequence capture was performed using Roche Nimblegen SeqCap EZ Human Exome v3.0. The five initial samples were sequenced on the Illumina HiSeq 2000 platform. Reads were aligned with Burrows-Wheeler Aligner (BWA) v 0.6.1 (ref. 11), duplicates were marked with Picard (see URLs), realignment was performed around indels, base quality was recalibrated and variant calling was performed with GATK 12 . On average, 5.9 Gb of sequence was generated per sample, and 92% (range of 90-95%) of the 64 Mb of captured target sequence was covered by at least tenfold read depth. Variants were annotated using the Ensembl Variant Effect Predictor 13 , and allele frequencies were obtained from the European population in the Phase 1 release of 1000 Genomes Project data 14 . We considered all variants predicted to disrupt protein-coding sequence with an allele frequency below 5% as potential causative variants underlying the Vel-negative phenotype.
Transcript profiling of blood precursor cells. A compendium of transcripts was generated as part of the BluePrint project 15 (see URLs) by sequencing RNA samples obtained from highly pure preparations (>95%) of five different primary progenitor and precursor blood cells (Supplementary Table 4) . Precursor cells for RBCs and platelets-erythroblasts and megakaryocytes, respectively-were generated by the culture of CD34 + hematopoietic stem cells (HSCs) for 10-12 d, as described previously 16 . Both the HSCs and other progenitor and precursor cells were isolated from the mononuclear cell fraction of donations of human cord blood by fluorescence-activated cell sorting using monoclonal antibodies against CD markers specific for certain stages of differentiation and lineage commitment (Supplementary Table 4) . Sorted cells, ranging in number from 20,000 to 100,000, were directly collected into TRIzol (Invitrogen) and stored at −80 °C. For paired-end sequencing, total RNA was isolated following the manufacturer's protocol, and an additional purification and concentration step was performed using the RNeasy mini kit (Qiagen). Transcriptome analysis libraries were prepared and amplified with the SMARTer Ultra Low Input RNA for Illumina sequencing and Advantage 2 PCR kit (Clontech) using 100 pg of total RNA as input. For multiplexing purposes, Bioscientific's NEXTflex ChIP Adapters were ligated to the library fragments. Paired-end sequencing of libraries was performed on a HiSeq 2000 system with TruSeq reagents (Illumina). All reagents were used according to the manufacturer's specifications.
Sequence reads were aligned to the February 2009 high-coverage assembly using GSNAP 17 version 2012-07-20 with trimming disabled. A maximum of five mismatches and identification of novel splice sites at genomic distances up to 100 kb from each other were allowed. Quantification of gene expression was performed using Cufflinks 18 v.1.3.0 allowing for multimap correction. Sequencing coverage over genomic loci was visualized in Integrative Genomics Viewer (IGV) 19 . SMIM1 transfections. HEK293T cells (7.5 × 10 5 ) were plated in 6-cm 2 plates and lentivirally transduced with mLwpRRLsSMIM1itNGFR. Forty-eight hours after transfection, cells were harvested and screened by flow cytometry using a Fortessa instrument (Beckman Coulter). Vel expression in the transfectants was assessed using human immune-purified IgG antibody to Vel (immune purification was performed by adsorption and elution from Vel-positive RBCs) and Alexa Fluor 488-labeled secondary antibody to human IgG (A-11013), and nerve growth factor receptor expression was assessed by antibody to CD 271 conjugated to APC (Miltenyi Biotec, ME20.4-1.H4).
Electrophoretic mobility shift assays (EMSAs). Nuclear extracts were prepared from K562 cells using NE-PER Nuclear and Cytoplasmic extraction reagents (Pierce). Oligonucleotides (Biolegio) were designed on the basis of the genomic sequence flanking variant rs1175550. The forward probes were fluorescently labeled with IRDye 700 tags on the 5′ end (Supplementary Table 3 ). Labeled probes were annealed to excess unlabeled PCR products using a standard protocol. DNA-protein binding reaction was performed by mixing 2-10 µg of nuclear extract with 0.2 pM annealed oligonucleotides in binding buffer (10 mM Tris (pH 7.5), 50 mM KCl and 1 mM DTT), 2.5% glycerol and 75 ng/µl poly(dIdC) in a final volume of 15 µl. The mixture was incubated for 30 min at room temperature, and PAGE was carried out at 25 °C on a 4.5% polyacrylamide gel. Fluorescence was visualized with the Odyssey Infrared Imaging System (Li-Cor Biosciences).
Zebrafish studies. General maintenance, collection and staging of the wild-type zebrafish were carried out according to the Zebrafish Book 20 . Embryos were maintained in egg water (60 mg/l Red Sea salts) at 28 °C until the appropriate stage. 
